Literature DB >> 19499921

A small-molecule inhibitor of Nipah virus envelope protein-mediated membrane fusion.

Sabine Niedermeier1, Katrin Singethan, Sebastian G Rohrer, Magnus Matz, Markus Kossner, Sandra Diederich, Andrea Maisner, Jens Schmitz, Georg Hiltensperger, Knut Baumann, Ulrike Holzgrabe, Jürgen Schneider-Schaulies.   

Abstract

Nipah virus (NiV), a highly pathogenic paramyxovirus, causes respiratory disease in pigs and severe febrile encephalitis in humans with high mortality rates. On the basis of the structural similarity of viral fusion (F) proteins within the family Paramyxoviridae, we designed and tested 18 quinolone derivatives in a NiV and measles virus (MV) envelope protein-based fusion assay beside evaluation of cytotoxicity. We found five compounds successfully inhibiting NiV envelope protein-induced cell fusion. The most active molecules (19 and 20), which also inhibit the syncytium formation induced by infectious NiV and show a low cytotoxicity in Vero cells, represent a promising lead quinolone-type compound structure. Molecular modeling indicated that compound 19 fits well into a particular protein cavity present on the NiV F protein that is important for the fusion process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499921     DOI: 10.1021/jm900411s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus.

Authors:  Bersabeh Tigabu; Lynn Rasmussen; E Lucile White; Nichole Tower; Mohammad Saeed; Alexander Bukreyev; Barry Rockx; James W LeDuc; James W Noah
Journal:  Assay Drug Dev Technol       Date:  2014-04       Impact factor: 1.738

Review 2.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

Review 3.  Emerging paramyxoviruses: molecular mechanisms and antiviral strategies.

Authors:  Hector C Aguilar; Benhur Lee
Journal:  Expert Rev Mol Med       Date:  2011-02-24       Impact factor: 5.600

4.  Off Label Antiviral Therapeutics for Henipaviruses: New Light Through Old Windows.

Authors:  Mohamad Aljofan; Michael K Lo; Paul A Rota; Wojtek P Michalski; Bruce A Mungall
Journal:  J Antivir Antiretrovir       Date:  2010-01-01

Review 5.  Small-Molecule Inhibition of Viral Fusion Glycoproteins.

Authors:  Han-Yuan Liu; Priscilla L Yang
Journal:  Annu Rev Virol       Date:  2021-07-01       Impact factor: 10.431

6.  The Role of Orthosteric Building Blocks of Bitopic Ligands for Muscarinic M1 Receptors.

Authors:  Daniela Volpato; Michael Kauk; Regina Messerer; Marcel Bermudez; Gerhard Wolber; Andreas Bock; Carsten Hoffmann; Ulrike Holzgrabe
Journal:  ACS Omega       Date:  2020-12-01

7.  Computational Identification of Potential Multitarget Inhibitors of Nipah Virus by Molecular Docking and Molecular Dynamics.

Authors:  Vinay Randhawa; Shivalika Pathania; Manoj Kumar
Journal:  Microorganisms       Date:  2022-06-09

8.  NipahVR: a resource of multi-targeted putative therapeutics and epitopes for the Nipah virus.

Authors:  Amit Kumar Gupta; Archit Kumar; Akanksha Rajput; Karambir Kaur; Showkat Ahmed Dar; Anamika Thakur; Kirti Megha; Manoj Kumar
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.